Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design

Abstract : Background: Slow-flow superficial vascular malformations (VMs) are rare congenital anomalies that can be responsible for pain and functional impairment. Currently, we have no guidelines for their management, which can involve physical bandages, sclerotherapy, surgery, anti-inflammatory or anti-coagulation drugs or no treatment. The natural history is progressive and worsening. Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that acts as a master switch in cell proliferation, apoptosis, metabolism and angio/lymphangiogenesis. Sirolimus directly inhibits the mTOR pathway, thereby inhibiting cell proliferation and angio/lymphangiogenesis. Case reports and series have reported successful use of sirolimus in children with different types of vascular anomalies, with heterogeneous outcomes.
Document type :
Journal articles
Complete list of metadatas

Cited literature [25 references]  Display  Hide  Download

https://hal.archives-ouvertes.fr/hal-01913363
Contributor : Jérôme Rollin <>
Submitted on : Friday, July 12, 2019 - 9:48:41 AM
Last modification on : Friday, July 19, 2019 - 1:31:38 AM

File

Maruani-2018-Treatment of volu...
Publisher files allowed on an open archive

Licence


Distributed under a Creative Commons Attribution 4.0 International License

Identifiers

Citation

Annabel Maruani, Olivia Boccara, Didier Bessis, Laurent Guibaud, Pierre Vabres, et al.. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design. Trials, BioMed Central, 2018, 19 (1), pp.340. ⟨10.1186/s13063-018-2725-1⟩. ⟨hal-01913363⟩

Share

Metrics

Record views

233

Files downloads

27